Altimmune Inc (ALT)

$7.08

-0.49

(-6.47%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Altimmune Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 362.0K → 37.0K (in $), with an average decrease of 89.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -16.06M → -31.64M (in $), with an average decrease of 40.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 14.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 283.8%

Performance

  • $6.99
    $7.72
    $7.08
    downward going graph

    1.25%

    Downside

    Day's Volatility :9.44%

    Upside

    8.29%

    downward going graph
  • $2.09
    $14.84
    $7.08
    downward going graph

    70.48%

    Downside

    52 Weeks Volatility :85.92%

    Upside

    52.29%

    downward going graph

Returns

PeriodAltimmune IncSector (Health Care)Index (Russel 2000)
3 Months
-23.71%
1.7%
0.0%
6 Months
198.73%
11.3%
0.0%
1 Year
35.37%
5.4%
1.3%
3 Years
-47.44%
13.9%
-22.1%

Highlights

Market Capitalization
522.5M
Book Value
$2.75
Earnings Per Share (EPS)
-1.66
PEG Ratio
0.0
Wall Street Target Price
21.13
Profit Margin
0.0%
Operating Margin TTM
-57308.11%
Return On Assets TTM
-25.0%
Return On Equity TTM
-46.63%
Revenue TTM
426.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
18000.0%
Gross Profit TTM
-70.5M
EBITDA
-83.0M
Diluted Eps TTM
-1.66
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.0
EPS Estimate Next Year
-1.77
EPS Estimate Current Quarter
-0.43
EPS Estimate Next Quarter
-0.42

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Altimmune Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 198.45%

Current $7.08
Target $21.13

Company Financials

FY18Y/Y Change
Revenue
10.3M
↑ 24792.58%
Net Income
-39.2M
↓ 15.63%
Net Profit Margin
-379.16%
↑ 111481.16%
FY19Y/Y Change
Revenue
5.8M
↓ 43.85%
Net Income
-20.5M
↓ 47.61%
Net Profit Margin
-353.71%
↑ 25.45%
FY20Y/Y Change
Revenue
8.2M
↑ 41.09%
Net Income
-49.0M
↑ 139.01%
Net Profit Margin
-599.2%
↓ 245.49%
FY21Y/Y Change
Revenue
4.4M
↓ 46.12%
Net Income
-96.2M
↑ 96.09%
Net Profit Margin
-2.2K%
↓ 1581.38%
FY22Y/Y Change
Revenue
-68.0K
↓ 101.54%
Net Income
-84.7M
↓ 11.91%
Net Profit Margin
124.6K%
↑ 126758.52%
FY23Y/Y Change
Revenue
426.0K
↓ 726.47%
Net Income
-88.4M
↑ 4.41%
Net Profit Margin
-20.8K%
↓ 145340.15%
Q3 FY22Q/Q Change
Revenue
2.0K
↓ 75.0%
Net Income
-23.5M
↑ 18.65%
Net Profit Margin
-1.2M%
↓ 928062.5%
Q4 FY22Q/Q Change
Revenue
-110.0K
↓ 5600.0%
Net Income
-20.2M
↓ 13.99%
Net Profit Margin
18.4K%
↑ 1194187.27%
Q1 FY23Q/Q Change
Revenue
21.0K
↓ 119.09%
Net Income
-18.4M
↓ 9.07%
Net Profit Margin
-87.6K%
↓ 105963.46%
Q2 FY23Q/Q Change
Revenue
6.0K
↓ 71.43%
Net Income
-16.1M
↓ 12.67%
Net Profit Margin
-267.7K%
↓ 180107.14%
Q3 FY23Q/Q Change
Revenue
362.0K
↑ 5933.33%
Net Income
-20.7M
↑ 28.7%
Net Profit Margin
-5.7K%
↑ 261973.11%
Q4 FY23Q/Q Change
Revenue
37.0K
↓ 89.78%
Net Income
-31.6M
↑ 53.07%
Net Profit Margin
-85.5K%
↓ 79806.0%
FY18Y/Y Change
Total Assets
54.8M
↓ 13.14%
Total Liabilities
6.4M
↓ 55.14%
FY19Y/Y Change
Total Assets
54.1M
↓ 1.26%
Total Liabilities
8.5M
↑ 32.62%
FY20Y/Y Change
Total Assets
245.1M
↑ 353.43%
Total Liabilities
19.2M
↑ 125.34%
FY21Y/Y Change
Total Assets
218.9M
↓ 10.71%
Total Liabilities
19.7M
↑ 2.55%
FY22Y/Y Change
Total Assets
206.9M
↓ 5.45%
Total Liabilities
21.6M
↑ 9.65%
FY23Y/Y Change
Total Assets
210.6M
↑ 1.79%
Total Liabilities
16.5M
↓ 23.55%
Q3 FY22Q/Q Change
Total Assets
225.3M
↑ 7.32%
Total Liabilities
20.2M
↑ 31.73%
Q4 FY22Q/Q Change
Total Assets
206.9M
↓ 8.15%
Total Liabilities
21.6M
↑ 6.85%
Q1 FY23Q/Q Change
Total Assets
187.1M
↓ 9.59%
Total Liabilities
19.4M
↓ 10.56%
Q2 FY23Q/Q Change
Total Assets
183.3M
↓ 2.01%
Total Liabilities
15.6M
↓ 19.37%
Q3 FY23Q/Q Change
Total Assets
166.6M
↓ 9.13%
Total Liabilities
16.2M
↑ 3.68%
Q4 FY23Q/Q Change
Total Assets
210.6M
↑ 26.46%
Total Liabilities
16.5M
↑ 2.26%
FY18Y/Y Change
Operating Cash Flow
-9.4M
↓ 53.55%
Investing Cash Flow
-1.0M
↓ 107.29%
Financing Cash Flow
32.5M
↑ 105.1%
FY19Y/Y Change
Operating Cash Flow
-9.6M
↑ 2.27%
Investing Cash Flow
-28.3M
↑ 2725.41%
Financing Cash Flow
12.5M
↓ 61.43%
FY20Y/Y Change
Operating Cash Flow
-34.4M
↑ 258.64%
Investing Cash Flow
-72.1M
↑ 154.88%
Financing Cash Flow
213.5M
↑ 1603.52%
FY21Y/Y Change
Operating Cash Flow
-78.2M
↑ 127.19%
Investing Cash Flow
87.5M
↓ 221.4%
Financing Cash Flow
65.1M
↓ 69.51%
FY22Y/Y Change
Operating Cash Flow
-62.6M
↓ 20.01%
Investing Cash Flow
-73.4M
↓ 183.86%
Financing Cash Flow
56.8M
↓ 12.78%
Q3 FY22Q/Q Change
Operating Cash Flow
-15.1M
↓ 9.9%
Investing Cash Flow
-25.4M
↓ 48.12%
Financing Cash Flow
32.1M
↑ 48.54%
Q4 FY22Q/Q Change
Operating Cash Flow
-17.3M
↑ 14.99%
Investing Cash Flow
981.0K
↓ 103.86%
Financing Cash Flow
-43.0K
↓ 100.13%
Q1 FY23Q/Q Change
Operating Cash Flow
-19.4M
↑ 12.14%
Investing Cash Flow
13.3M
↑ 1255.96%
Financing Cash Flow
-302.0K
↑ 602.33%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.4M
↓ 0.12%
Investing Cash Flow
4.0M
↓ 70.03%
Financing Cash Flow
13.1M
↓ 4426.16%
Q3 FY23Q/Q Change
Operating Cash Flow
-20.5M
↑ 5.7%
Investing Cash Flow
4.4M
↑ 10.41%
Financing Cash Flow
588.0K
↓ 95.5%

Technicals Summary

Sell

Neutral

Buy

Altimmune Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Altimmune Inc
Altimmune Inc
-17.0%
198.73%
35.37%
-47.44%
159.34%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Altimmune Inc
Altimmune Inc
NA
NA
0.0
-1.0
-0.47
-0.25
NA
2.75
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Altimmune Inc
Altimmune Inc
Buy
$522.5M
159.34%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • Ameriprise Financial Inc

    5.90%

  • BlackRock Inc

    5.71%

  • Vanguard Group Inc

    5.04%

  • TANG CAPITAL MANAGEMENT LLC

    3.88%

  • Nuveen Asset Management, LLC

    2.44%

  • Geode Capital Management, LLC

    1.68%

Corporate Announcements

  • Altimmune Inc Earnings

    Altimmune Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current

Organization
Altimmune Inc
Employees
59
CEO
Dr. Vipin K. Garg Ph.D.
Industry
Commercial Services

Discover More

FAQs